Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Jazz Pharmaceuticals Plc, Medical Devices Deals, 2012 to YTD 2018 12
Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13
Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deal Details 16
Asset Purchase 16
JAZZ Pharma Acquires Rare Pediatric Disease Priority Review Voucher from Spark Therapeutics for USD110 Million 16
Jazz Pharma Acquires Defibrotide from Sigma-Tau Pharma for USD250 Million 17
Jazz Pharma Acquires Rights To ADX-N05 From Aerial BioPharma For US$125 Million 19
Venture Financing 20
Arrivo BioVentures Raises USD49 Million in Venture Financing 20
Alize Pharma Raises USD1.9 Million in Venture Financing 21
Alize Pharma Raises USD6.4 Million in Series A Financing 22
Celator Pharma Raises US$39 Million In Venture Financing 23
Celator Pharma Raises USD4.1 Million in Venture Financing 24
Alize Pharma Raises US$4 Million In Venture Financing 25
Partnerships 26
Jazz Pharma and MD Anderson Cancer Center Enter into Agreement 26
Jazz Pharma and ImmunoGen Enter into Research and Option Agreement 27
The Leukemia & Lymphoma Society Enters Into Co-Development Agreement With Celator Pharma For CPX-351 28
Gentium Enters Into Distribution Agreement With PharmaSwiss For Defibrotide 29
Swedish Orphan Biovitrum Enters Into Distribution Agreement With Gentium For Defibrotide 30
Merger 31
Jazz Pharma Merges With Azur Pharma In All Stock Transaction 31
Licensing Agreements 33
Jazz Pharma Enters into License Agreement with XL-protein 33
Nippon Shinyaku Enters into Licensing Agreement with Jazz Pharma 34
Jazz Pharma Amends Licensing Agreement with Pfenex 35
Alize Pharma Enters into Licensing Agreement with New Paradigm Therapeutics 37
Jazz Pharma Enters Into Licensing Agreement With Concert Pharma For C-10323 38
EUSA Pharma Enters Into Licensing Agreement With Alize Pharma For ASPAREC 40
Equity Offering 41
Celator Pharma Raises USD43.7 Million Public Offering of Shares for 41
Celator Pharma Raises USD15 Million in Public Offering of Shares and Warrants 43
Debt Offering 45
Jazz Pharma Raises USD575 Million in Private Placement of Notes Due 2024 45
Jazz Pharma Raises USD575 Million in Private Placement of 1.875% Senior Notes Due 2021 46
Asset Transactions 47
TerSera Therapeutics to Acquire Prialt from Jazz Pharma for USD80 Million 47
Elsalys Biotech Acquires Rights of LEUKOTAC from Jazz Pharma 48
Aytu BioScience Acquires ProstaScint from Jazz Pharma 49
Essex Bidco Acquires Assets from Jazz Pharma 50
Lantheus Medical Imaging Acquires Quadramet from Jazz Pharma 52
Meda Completes Acquisition Of Women’s Health Business From Jazz Pharma For US$95 Million 53
Acquisition 55
Jazz Pharma Completes Tender Offer to Acquire Celator Pharma 55
Jazz Pharma Acquires Alize Pharma 57
AstraZeneca May Acquire Ariad Pharma 58
Jazz Pharma Completes Acquisition Of Majority Interest In Gentium For US$993.4 Million 60
Jazz Pharma Acquires Eusa Pharma For Up To US$730 Million 62
Jazz Pharmaceuticals Plc – Key Competitors 65
Jazz Pharmaceuticals Plc – Key Employees 66
Jazz Pharmaceuticals Plc – Locations And Subsidiaries 67
Head Office 67
Other Locations & Subsidiaries 67
Recent Developments 69
Financial Announcements 69
Nov 06, 2018: Jazz Pharmaceuticals announces third quarter 2018 financial results 69
Aug 07, 2018: Jazz Pharmaceuticals announces second quarter 2018 financial results 71
May 08, 2018: Jazz Pharmaceuticals Reports First Quarter 2018 Financial Results 73
Feb 27, 2018: Jazz Pharmaceuticals Announces Full Year And Fourth Quarter 2017 Financial Results 75
Nov 07, 2017: Jazz Pharmaceuticals Announces Third Quarter 2017 Financial Results 77
Aug 08, 2017: Jazz Pharmaceuticals Announces Second Quarter 2017 Financial Results 78
May 09, 2017: Jazz Pharmaceuticals Announces First Quarter 2017 Financial Results 79
Feb 28, 2017: Jazz Pharmaceuticals Announces Full Year And Fourth Quarter 2016 Financial Results 81
Corporate Communications 83
Dec 04, 2017: Jazz Pharmaceuticals Announces Appointment Of Daniel Swisher As President And Chief Operating Officer 83
Product News 84
08/03/2017: Jazz Pharmaceuticals Announces FDA Approval of Vyxeos Liposome for Injection for the Treatment of Adults with Newly-Diagnosed Therapy-Related Acute Myeloid Leukemia (t-AML) or AML with Myelodysplasia-Related Changes (AML-MRC) 84
08/03/2017: Jazz Pharmaceuticals Announces Webcast for Vyxeos Investor Update 85
03/19/2018: Clinigen appointed by Jazz Pharmaceuticals to manage Managed Access Program for Vyxeos (CPX-351) outside the United States 86
02/08/2018: National Comprehensive Cancer Network adds Jazz Pharmaceuticals’ Vyxeos (daunorubicin and cytarabine) Liposome for Injection to Clinical Practice Guidelines in Oncology 87
Product Approvals 88
Nov 03, 2017: Jazz Pharmaceuticals Submits Vyxeos Marketing Authorization Application to European Medicines Agency for Treatment of Certain Types of High-Risk Acute Myeloid Leukemia 88
May 31, 2017: Jazz Pharmaceuticals Announces FDA Acceptance of NDA for VYXEOS (CPX-351), an Investigational Treatment for Acute Myeloid Leukemia, with Priority Review Status 89
Apr 03, 2017: Jazz Pharmaceuticals Completes Rolling Submission of New Drug Application for Vyxeos (CPX-351), an Investigational Treatment for Acute Myeloid Leukemia 90
Clinical Trials 91
Nov 01, 2017: Jazz Pharmaceuticals to Present Abstracts on Vyxeos at ASH 2017 Annual Meeting 91
Jan 17, 2017: Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 3 Clinical Trial Evaluating Defibrotide for the Potential Prevention of VOD in High Risk Patients 94
Appendix 95
Methodology 95
About GlobalData 95
Contact Us 95
Disclaimer 95
Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Jazz Pharmaceuticals Plc, Deals By Therapy Area, 2012 to YTD 2018 10
Jazz Pharmaceuticals Plc, Medical Devices Deals, 2012 to YTD 2018 12
Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13
JAZZ Pharma Acquires Rare Pediatric Disease Priority Review Voucher from Spark Therapeutics for USD110 Million 16
Jazz Pharma Acquires Defibrotide from Sigma-Tau Pharma for USD250 Million 17
Jazz Pharma Acquires Rights To ADX-N05 From Aerial BioPharma For US$125 Million 19
Arrivo BioVentures Raises USD49 Million in Venture Financing 20
Alize Pharma Raises USD1.9 Million in Venture Financing 21
Alize Pharma Raises USD6.4 Million in Series A Financing 22
Celator Pharma Raises US$39 Million In Venture Financing 23
Celator Pharma Raises USD4.1 Million in Venture Financing 24
Alize Pharma Raises US$4 Million In Venture Financing 25
Jazz Pharma and MD Anderson Cancer Center Enter into Agreement 26
Jazz Pharma and ImmunoGen Enter into Research and Option Agreement 27
The Leukemia & Lymphoma Society Enters Into Co-Development Agreement With Celator Pharma For CPX-351 28
Gentium Enters Into Distribution Agreement With PharmaSwiss For Defibrotide 29
Swedish Orphan Biovitrum Enters Into Distribution Agreement With Gentium For Defibrotide 30
Jazz Pharma Merges With Azur Pharma In All Stock Transaction 31
Jazz Pharma Enters into License Agreement with XL-protein 33
Nippon Shinyaku Enters into Licensing Agreement with Jazz Pharma 34
Jazz Pharma Amends Licensing Agreement with Pfenex 35
Alize Pharma Enters into Licensing Agreement with New Paradigm Therapeutics 37
Jazz Pharma Enters Into Licensing Agreement With Concert Pharma For C-10323 38
EUSA Pharma Enters Into Licensing Agreement With Alize Pharma For ASPAREC 40
Celator Pharma Raises USD43.7 Million Public Offering of Shares for 41
Celator Pharma Raises USD15 Million in Public Offering of Shares and Warrants 43
Jazz Pharma Raises USD575 Million in Private Placement of Notes Due 2024 45
Jazz Pharma Raises USD575 Million in Private Placement of 1.875% Senior Notes Due 2021 46
TerSera Therapeutics to Acquire Prialt from Jazz Pharma for USD80 Million 47
Elsalys Biotech Acquires Rights of LEUKOTAC from Jazz Pharma 48
Aytu BioScience Acquires ProstaScint from Jazz Pharma 49
Essex Bidco Acquires Assets from Jazz Pharma 50
Lantheus Medical Imaging Acquires Quadramet from Jazz Pharma 52
Meda Completes Acquisition Of Women's Health Business From Jazz Pharma For US$95 Million 53
Jazz Pharma Completes Tender Offer to Acquire Celator Pharma 55
Jazz Pharma Acquires Alize Pharma 57
AstraZeneca May Acquire Ariad Pharma 58
Jazz Pharma Completes Acquisition Of Majority Interest In Gentium For US$993.4 Million 60
Jazz Pharma Acquires Eusa Pharma For Up To US$730 Million 62
Jazz Pharmaceuticals Plc, Key Competitors 65
Jazz Pharmaceuticals Plc, Key Employees 66
Jazz Pharmaceuticals Plc, Other Locations 67
Jazz Pharmaceuticals Plc, Subsidiaries 67
List of Figures
Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8
Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Jazz Pharmaceuticals Plc, Medical Devices Deals, 2012 to YTD 2018 12